Discontinued — last reported Q3 '24
Zoetis Contract Manufacturing and Human Health Diagnostics — Revenue increased by 16.7% to $21.00M in Q3 2024 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from $21.00M to $21.00M. This is a positive signal — higher values indicate stronger performance for this metric.
An increase suggests successful monetization of idle manufacturing assets or growth in human diagnostic market penetration, while a decrease may indicate a strategic shift away from non-core activities or loss of manufacturing contracts.
This metric represents the total net sales generated from contract manufacturing services provided to third parties and...
Peers in the animal health or pharmaceutical space often report similar non-core revenue under 'Other' or 'Contract Services' segments, which typically exhibit lower margins than core proprietary product lines.
zts_segment_contract_manufacturing_and_human_health_diagnostics_revenue| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $20.00M | $21.00M | $18.00M | $18.00M | $23.00M | $17.00M | $20.00M | $21.00M | $20.00M | $18.00M | $21.00M |
| QoQ Change | — | +5.0% | -14.3% | +0.0% | +27.8% | -26.1% | +17.6% | +5.0% | -4.8% | -10.0% | +16.7% |
| YoY Change | — | — | — | -10.0% | +9.5% | -5.6% | +11.1% | -8.7% | +17.6% | -10.0% | +0.0% |